Esperion Therapeutics Inc (NASDAQ:ESPR) reached a new 52-week high on Thursday . The company traded as high as $76.98 and last traded at $72.61, with a volume of 35021 shares changing hands. The stock had previously closed at $70.11.
A number of analysts recently weighed in on the company. Chardan Capital restated a “hold” rating and issued a $65.00 price objective on shares of Esperion Therapeutics in a report on Friday, January 31st. ValuEngine downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, January 3rd. BidaskClub upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday. Citigroup downgraded Esperion Therapeutics from a “buy” rating to a “neutral” rating and increased their price objective for the company from $73.00 to $82.00 in a report on Friday. Finally, Cowen restated a “buy” rating on shares of Esperion Therapeutics in a report on Wednesday, November 6th. Six research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $68.00.
The company has a quick ratio of 4.41, a current ratio of 4.41 and a debt-to-equity ratio of 0.01. The firm has a market cap of $1.93 billion, a P/E ratio of -19.05 and a beta of 2.13. The stock’s 50-day simple moving average is $58.70 and its 200 day simple moving average is $45.77.
In other news, major shareholder Target N. V. Biotech purchased 20,000 shares of the business’s stock in a transaction on Thursday, January 23rd. The shares were acquired at an average price of $51.84 per share, with a total value of $1,036,800.00. Following the completion of the transaction, the insider now owns 3,747,964 shares of the company’s stock, valued at approximately $194,294,453.76. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 7.70% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC bought a new position in shares of Esperion Therapeutics during the 3rd quarter worth about $42,000. Tower Research Capital LLC TRC boosted its position in shares of Esperion Therapeutics by 21.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,361 shares of the biopharmaceutical company’s stock worth $81,000 after purchasing an additional 238 shares in the last quarter. Ancora Advisors LLC bought a new position in shares of Esperion Therapeutics during the 4th quarter worth about $134,000. Royal Bank of Canada boosted its position in shares of Esperion Therapeutics by 38.1% during the 2nd quarter. Royal Bank of Canada now owns 2,938 shares of the biopharmaceutical company’s stock worth $137,000 after purchasing an additional 811 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in shares of Esperion Therapeutics during the 1st quarter worth about $186,000. 98.71% of the stock is currently owned by institutional investors and hedge funds.
About Esperion Therapeutics (NASDAQ:ESPR)
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Further Reading: Stock Portfolio Tracker
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.